HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Says Lindane Remains Viable Lice Killer, Denies Ban Request

This article was originally published in The Rose Sheet

Executive Summary

FDA finds no reason why prescription lindane should be banned from use in lice/scabies treatments, as requested by the Natural Resources Defense Council. The Rx ingredient’s use, and associated adverse events, have declined over the years with tighter labeling requirements, the agency notes.

You may also be interested in...



Lindane Ban Request Presents Chance To Promote Natural Lice Solutions

Lindane, used as an insecticide agent in lice treatments, is hazardous, ineffective and bad for the environment, Congressman Edward J Markey, D-Mass., says in a letter to FDA. With the use of harsh chemicals increasingly under attack, brands that offer natural solutions can shine.

Owner Of Sunscreen Testing Lab AMA Awaits Sentencing Following Guilty Plea In US Federal Case

Gabriel Letizia Jr. potentially faces up to seven years in prison after admitting to defrauding AMA Laboratories customers of more than $46m by sending them bogus testing reports. The US FDA, which participated in the investigation, has not commented publicly on the implications for improperly tested sunscreens and other products.

California VOC Limits Will Challenge Industry To Maintain Fragrance Quality, Consumer Acceptance

The Fragrance Creators Association and Personal Care Products Council remain concerned that more stringent VOC limits for personal fragrance products in California, as approved by the Air Resources Board in March, will be disproportionately burdensome for industry and potentially detrimental to the market.

UsernamePublicRestriction

Register

RS018387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel